Daiichi's Benicar accord brings payout over drugs to US$339m
Wilmington, Delaware
DAIICHI Sankyo Inc's settlement of thousands of lawsuits blaming the company's blood pressure drugs for causing intestinal damage brings to US$339 million the amount the drugmaker has paid for its handling of the medicines.
Daiichi officials agreed on Monday to pay US$300 million to resolve patient suits over its Benicar, Benicar HCT, Azor and Tribenzor blood pressure treatments. The accord comes more than two years after the Chuo-Ku, Japan-based company paid US$39 million to resolve the US government's allegations that it paid illegal kickbacks to doctors who prescribed the medicines.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Restaurant Brands tops estimates as Burger King overhaul pays off
Walmart to shut all health centers in US over lack of profitability
Coca-Cola raises annual sales forecast on global demand, higher prices
Dying salmon trouble Norway’s vast fish-farm industry
Fast-fashion giant Shein wants to sell skincare, toothpaste and toys, too
Billionaire Geiger is said to near US$7 billion L’Occitane buyout